case report

History and Examination
A 26-year-old man with acromegaly was admitted to the Department of Endocrinology, Metabolism and Internal Medicine for evaluation and treatment. A diagnosis had been made when he was 23 years of age because of visual disturbances in the left eye and severe headaches. At that time, he presented with all the classic clinical features of active acromegaly including headaches, joint pain, excessive perspiration as well as acral enlargement and facial dysmorphia. In addition, he developed signs of hypopituitarism. Laboratory tests confirmed GH hypersecretion and hypopituitarism requiring levothyroxine, hydrocortisone, and testosterone replacements. At the time of diagnosis, MRI of the head showed an invasive pituitary macroadenoma 5.6 (height) × 2.5 (anteroposterior diameter) × 3.6 (width) cm with infiltration of both cavernous sinuses, intrasellar and extrasellar extension, compression of the optic chiasm, and pushing up into the third ventricle (Fig. 1 ).
Initial Treatment
The patient underwent transsphenoidal partial resection of the pituitary tumor mass. Histopathological examination confirmed the diagnosis of pituitary adenoma with positive immunohistochemical staining for GH markers.
He received both pre-and postoperative long-acting SSA. Initially, he was treated with octreotide (30 mg intramuscularly) every 28 days, then with lanreotide (120 mg subcutaneously) for the same duration. However, during treatment with "cold" SSA, the patient did not attain biochemical remission.
Postoperatively, the visual field defects ameliorated, and the patient required continual hormone replacement therapy. Six months later, he noticed a decrease in his visual field, and an increase in tumor size was observed on MRI.
Subsequent Treatments
One year after the operation the tumor increased in size and still extended up into the optic chiasm and third ventricle, although without any signs or symptoms of chiasmatic compression. Therefore, the patient received a 50-Gy course of intensity-modulated radiation delivered to the pituitary tumor mass over 6 weeks.
One and a half years after irradiation, the patient still presented with clinically and biochemically active disease, and the pituitary tumor mass measurements on MRI were as follows: intrasellar part: 2.2 (height) × 2.6 (anteroposterior diameter) × 2.7 (width) cm and suprasellar part: 3.3 × 1.6 × 1.4 cm (Fig. 2 left) . The patient underwent 68 Ga-DOTATATE PET/CT scanning, and the presence of SSTR expression in the pituitary tumor was confirmed. Because of the tumor size and persistent disease activity, we decided to treat the patient with the radiolabeled SSA 90 Y-DOTATATE. Before administration of the 90 Y-DOT-ATATE, basal hormone studies showed values still indicative of active disease (Fig. 3) . The patient was treated with a total dose of 400 mCi of 90 Y-DOTATATE (100 mCi administered every 3 months). The treatment led to regression in the tumor size over 12 months to 1.8 × 2.3 × 2.7 cm for the intrasellar part and 2.8 × 1.0 × 1.0 cm for the suprasellar part (Fig. 2 right) . Moreover, the young man had attained for the first time partial biochemical remission.
discussion
The primary goal in the management of acromegaly is to reverse the effects of GH hypersecretion and to decrease the tumor size as much as possible. 2, 4 According to current guidelines on GH-secreting pituitary tumor treatment, surgery is the primary option when an experienced surgeon is available and the tumor is resectable, especially for small well-circumscribed adenomas. Somatostatin analogs are commonly introduced prior to surgery.
14 They may be considered for first-line therapy for patients with invasive tumors who are unlikely to attain surgical remission and who do not require surgical debulking to treat mass effect symptoms such as visual field deficits. Moreover, if the operation does not lead to biochemical control of the disease, SSA treatment should be continued. 5, 13 In our patient, medical monotherapy with long-lasting octreotide or lanreotide did not result in an improvement in disease control, nor did it influence the tumor size. It was considered to be part of a combination therapy consisting of SSA and cabergoline or pegvisomant; however, the patient did not agree to the cabergoline because of its high cost. 17 Moreover, current data show that pegvisomant therapy may lead to GH-producing pituitary tumor growth.
3, 12 We did not qualify the patient for pegvisomant treatment because this medication has been shown to cause a further increase in tumor size. Therefore, therapy with pegvisomant in our patient with the giant pituitary adenoma could bring a significant risk of tumor progression resulting in the deterioration of his clinical status, especially visual field problems. Nonetheless, according to the ACROSTUDY, pegvisomant is currently available as a third-line therapy. 6 No data are yet available to indicate whether the size of a GH-producing tumor is modified by treatment with SSA coupled with 90 Y-DOTATATE. Somatostatin receptor expression can be evaluated using immunohistochemistry or receptor scintigraphy. 8 In our case, to assess the expression of SSTR we used 68 Ga-DOTATATE PET/CT and 99m Tc-HYNIC-TOC receptor scintigraphy. In such studies, a pituitary adenoma is highlighted as the focus of increased tracer accumulation. It shows high expression of SSTR Types 2 and 4. This is the basic aspect of eligibility for treatment with "hot" (labeled) SSA (for example, 90 Y-DOTATATE).
Somatostatin receptor expression in neuroendocrine tumors using 68 Ga-DOTATATE PET/CT was carefully studied. 10 Sansovini et al. found that treatment with the radiolabeled SSA 177 Lu-DOTATATE for advanced pancreatic neuroendocrine tumors was effective. 19 Tissues exposed to radiation during treatment include the bone marrow and kidneys. During the course of therapy, a mixture of amino acids (lysine and arginine) is given to protect the renal tubules. In addition, cell blood count should be determined postadministration. This therapy is highly effective and safe. 9 The present case features the first patient in whom therapy with "hot" SSA influences pituitary tumor size. During treatment, the tumor mass decreased in size, especially within the suprasellar part. Moreover, serum concentrations of insulin-like growth factor (IGF)-1 and GH decreased but did not fall within the normal range according to the current guidelines. The patient improved symptomatically, and the therapy was well tolerated with transient adverse effects including anemia and leucopenia.
To our knowledge, this is the second report of an acromegalic patient treated with SSA coupled with 90 Y-DOT-ATATE. The study concerning radiolabeled SSA therapy for pituitary tumors was performed by Kaminski and coauthors at the Military Institute of Health Services in Warsaw, Poland. 7 The researchers evaluated the response of functional pituitary tumors to SSA coupled with the b-emitter 90 Y. They described a decrease of adrenocorticotropic hormone (ACTH) in patients with Nelson's syndrome (ACTH-secreting pituitary tumors treated with bilateral adrenalectomy) and a GH decrease in acromegalic patients. Moreover, clinical improvement was attained in all cases. These authors did not evaluate pituitary tumor size, nor did they mention it in the abstract.
Tumor aggressiveness in the patient in our case may reflect a subgroup of patients in whom close follow-up of tumor size is mandatory with any treatment. New pharmacological approaches in the treatment of aggressive pituitary tumors should be considered.
